Rinsho Ketsueki
Online ISSN : 1882-0824
Print ISSN : 0485-1439
ISSN-L : 0485-1439
Search
Advanced search
OR
Browse
Search
Volume 55, Issue 6
Displaying 1-13 of 13 articles from this issue
Show all abstracts
    • |<
    • <
    • 1
    • >
    • >|
Picture in Clinical Hematology
Review
  • Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation
    Navneet S. MAJHAIL, J. Douglas RIZZO, Stephanie J. LEE, Mahmoud ALJURF ...
    2014 Volume 55 Issue 6 Pages 607-632
    Published: 2014
    Released on J-STAGE: June 27, 2014
    DOIhttps://doi.org/10.11406/rinketsu.55.607
    JOURNAL RESTRICTED ACCESS
    Show abstractHide abstract
    Advances in hematopoietic cell transplantation (HCT) technology and supportive care techniques have led to improvements in long-term survival after HCT. Emerging indications for transplantation, introduction of newer graft sources (eg, umbilical cord blood) and transplantation of older patients using less intense conditioning regimens have also contributed to an increase in the number of HCT survivors. These survivors are at risk for developing late complications secondary to pre-, peri-, and posttransplantation exposures and risk factors. Guidelines for screening and preventive practices for HCT survivors were published in 2006. An international group of transplantation experts was convened in 2011 to review contemporary literature and update the recommendations while considering the changing practice of transplantation and international applicability of these guidelines. This review provides the updated recommendations for screening and preventive practices for pediatric and adult survivors of autologous and allogeneic HCT.
    View full abstract
    Download PDF (893K)
The 75th Annual Meeting of the Japanese Society of Hematology
Presidential Symposium
Symposium 4
Case Reports
  • Herpes simplex virus type 2 fulminant hepatitis after umbilical cord blood transplantation for acute myeloid leukemia
    Mitsuhiro YUASA, Kazuya ISHIWATA, Takeshi SUGIO, Daisuke KAJI, Hikari ...
    2014 Volume 55 Issue 6 Pages 682-686
    Published: 2014
    Released on J-STAGE: June 27, 2014
    DOIhttps://doi.org/10.11406/rinketsu.55.682
    JOURNAL RESTRICTED ACCESS
    Show abstractHide abstract
    This report describes a 41-year-old patient, who developed herpes simplex virus type 2 (HSV-2)-hepatitis after umbilical cord blood transplantation (CBT). The patient had received allogeneic bone marrow transplantation from an unrelated donor for acute myeloid leukemia (AML) not in remission. AML relapsed 18 months after the first transplantation, and CBT was performed. AML relapsed again 5 months later and the patient was given chemotherapy. Although there was no active chronic graft-versus-host disease, liver dysfunction appeared, and one week later, progressed to acute liver failure. Viral screening of blood by PCR including hepatitis B and C viruses, human immunodeficiency virus, Epstein-Barr virus, cytomegalovirus, herpes simplex virus type 1 and HSV-2 revealed elevation of HSV-2 (2.34×104 copies/ml). We diagnosed the patient as having HSV-2 acute hepatitis, and initiated treatment with antiviral drugs (acyclovir, foscarnet) and plasma exchange. However, liver functions deteriorated rapidly, and the patient died on day 6 after the onset of acute liver failure. Although HSV hepatitis is very rare after allogeneic stem cell transplantation, it is rapidly progressive and associated with a high mortality rate. Thus, early diagnosis with prompt antiviral intervention is recommended.
    View full abstract
    Download PDF (1769K)
  • Successful treatment with dasatinib for polycythemia vera patient emerging BCR-ABL positive clone during 13 years of treatment
    Makiko TAKIZAWA, Akihiko YOKOHAMA, Tomomi SEKIGAMI, Hiromi KOISO, Taku ...
    2014 Volume 55 Issue 6 Pages 687-691
    Published: 2014
    Released on J-STAGE: June 27, 2014
    DOIhttps://doi.org/10.11406/rinketsu.55.687
    JOURNAL RESTRICTED ACCESS
    Show abstractHide abstract
    Herein, we report a patient with polycythemia vera (PV) who exhibited Philadelphia chromosome (Ph) positive CML-like clinical features after 13 years of hydroxycarbamide administration and successful treatment with a tyrosine kinase inhibitor (TKI). She was 64 years old when initially diagnosed with PV and was confirmed to be negative for BCR-ABL translocation. Thirteen years later, with increasing white blood cell and platelet counts, a BCR-ABL positive clone emerged and the JAK2V617F mutation disappeared. After TKI treatment, the BCR-ABL copy number decreased and the JAK2V617F mutation was again detected. Furthermore, MPN clinical features were observed. This case provides insights into the clonal divergence and growth advantage of the Ph positive clone over the MPN clone. Whether JAK2V617F is an MPN initiating event or a secondary mutation has been a point of discussion for the past several years. This issue is also considered in the present report.
    View full abstract
    Download PDF (856K)
  • T315I positive promyelocytic crisis of chronic myeloid leukemia
    Eri YAMAMOTO, Etsuko YAMAZAKI, Yasufumi ISHIYAMA, Satoshi KOYAMA, Yosh ...
    2014 Volume 55 Issue 6 Pages 692-696
    Published: 2014
    Released on J-STAGE: June 27, 2014
    DOIhttps://doi.org/10.11406/rinketsu.55.692
    JOURNAL RESTRICTED ACCESS
    Show abstractHide abstract
    Promyelocytic crisis (PMC) of chronic myelogenous leukemia (CML) is relatively rare. We report a patient who progressed to PMC with a T315I mutation during the initial treatment with dasatinib for CML. He obtained hematological remission after combination therapy with all-trans retinoic acid and chemotherapy for PMC, and PML-RARA was not detected by FISH analysis. Arsenic trioxide (ATO) and imatinib therapy induced a second complete cytogenetic response, and PML-RARA mRNA detected by real-time quantitative RT-PCR dropped below the detection limit. Finally, allogeneic stem cell transplantation was performed. This case suggests that combination therapy with imatinib and ATO achieves favorable outcomes for PMC.
    View full abstract
    Download PDF (1232K)
  • Thrombopoietin receptor agonists administration for acute exacerbation of chronic idiopathic thrombocytopenic purpura and subsequent anticoagulant therapy for accompanying deep venous thrombosis of the lower limbs
    Hiroki KAWANO, Tomohide SUZUKI, Shinichi ISHII, Kanako WAKAHASHI, Yuko ...
    2014 Volume 55 Issue 6 Pages 697-702
    Published: 2014
    Released on J-STAGE: June 27, 2014
    DOIhttps://doi.org/10.11406/rinketsu.55.697
    JOURNAL RESTRICTED ACCESS
    Show abstractHide abstract
    We report two patients (70- and 49-year-old Japanese men) with acute exacerbation of chronic idiopathic thrombocytopenic purpura (ITP) and deep venous thrombosis of the lower extremities. Both were successfully managed with thrombopoietin receptor agonist (TPO-RA) administration. Both had ITP refractory to steroid treatment. Their immature platelet fraction (absolute-IPF) counts were increased and paralleled the platelet recoveries after TPO-RA (eltrombopag and romiplostim, respectively) without progression of thrombosis. Although ITP has recently been evaluated as a thrombophilic disorder, reports on acute exacerbation of ITP with newly diagnosed thrombosis are limited, and the pathophysiology and association between ITP and thrombosis remain to be elucidated. Moreover, the influences of TPO-RA on thrombosis are still controversial. To our knowledge, this is the first case report describing patients with exacerbation of ITP who developed thrombosis and were treated with TPO-RA. The outcomes of our cases underscore the importance of monitoring thrombosis and not delaying the initiation of anticoagulation treatment during the use of TPO-RA.
    View full abstract
    Download PDF (999K)
A Short Report
Introduce My Article
    • |<
    • <
    • 1
    • >
    • >|
feedback
 Top